Skip to main content

Ibogaine in the News

Ibogaine in the news

Ibogaine In The news

Ibogaine is dominating recent news headlines through major federal pushes, clinical milestones, and research initiatives:
    • FDA Public Comment & Trial Design: The U.S. Food and Drug Administration issued a Request for Information (RFI) to gather public input and data on early-phase clinical trial designs for ibogaine drug products, with the comment window open through November 20, 2026 (Docket No. FDA-2026-N-10429). You can review the announcement on the FDA Press Announcements Page. [1]
  • White House & Interagency Push: Driven by an executive order to accelerate medical treatments for serious mental illness and veteran suicide crises, the administration, HHS, the VA, and the FDA are coordinating on fast-tracked research, federal funding, and real-world evidence pathways for psychedelics like ibogaine. [1, 2]

  • Stanford Veteran Study Results: Stanford Medicine published a 12-month observational trial in Translational Psychiatry examining special forces veterans treated with oral ibogaine in Mexico for traumatic brain injury (TBI), PTSD, depression, and anxiety, reporting sustained long-term remission rates. Read the summary via Stanford Medicine News. [1]

  • Domestic U.S. Trials: Barrow Neurological Institute and Arizona State University (ASU) announced a $5 million state-funded clinical trial evaluating ibogaine safety and efficacy for PTSD, depression, and addiction, with participant enrollment slated to begin in 2027. [1]

  • Legal and Safety Status: Ibogaine remains a Schedule I controlled substance and is illegal outside of approved research settings in the United States, carrying known cardiac and neurological risks that require tight medical supervision. [1, 2]

Would you like to explore:
The specific medical or cardiac risks associated with ibogaine?Details on the federal executive order or funding programs?Current legal status and state-level policy efforts?

  • U.S. Food and Drug Administration (.gov)

    FDA Seeks Public Input to Support Ibogaine Research | FDA
    October 5, 2026 — Action: FDA issued a Request for Information (RFI) seeking public input, comments, and data on early-phase clinical trial designs …

  • Stanford Medicine

    One year after taking ibogaine, veterans find continued relief from PTSD
    October 6, 2026 — Study: Stanford Medicine observational trial published in Translational Psychiatry (Aug 12). Participants: 30 special forces veter…

  • ASU News

    Barrow, ASU embark on one of first clinical trials of ibogaine in the US | ASU News
    August 31, 2026 — Partnership: Barrow Neurological Institute and Arizona State University (ASU); $5 million grant from Arizona Department of Health …

This is for informational purposes only. For medical advice or diagnosis, consult a professional. AI responses may include mistakes. Learn more